Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Atherosclerosis. 2018 May 24;275:43–49. doi: 10.1016/j.atherosclerosis.2018.05.045

Fig. 1.

Fig. 1

ASO-Fsp27 therapy ameliorates diet-induced obesity and hypertriglyceridemia. Ldlr−/− mice were fed a WD for 12 weeks while injected twice weekly with saline, ASO-ctrl, or ASO-Fsp27.

(A) Weekly body weight gain. (B) Final body weight. (C) Caloric intake during the last week of the experiment. (D and E) Plasma lipid contents on weeks 0 and 12, and FPLC lipoprotein profiles on week 12. Data are shown as means ± s.e.m. (n = 14). *p ≤ 0.05, **p ≤ 0.01, compared to saline; ‡p ≤ 0.05, ‡‡p ≤ 0.01 compared to ASO-ctrl.